Proportions of blood-borne Vd1þ and Vd2þ T-cells are associated with overall survival of melanoma patients treated with ipilimumab - Archive ouverte HAL Access content directly
Journal Articles European Journal of Cancer Year : 2016

Proportions of blood-borne Vd1þ and Vd2þ T-cells are associated with overall survival of melanoma patients treated with ipilimumab

(1, 2) , (1, 2) , (2) , (3) , (4) , (5, 4) , (4) , (6) , (7, 8) , (7, 8) , (9) , (9) , (10) , (10) , (11) , (12, 13) , (13, 12) , (4, 5) , (3) , (1) , (2) , (2)
1
2
3
4
5
6
7
8
9
10
11
12
13

Abstract

Human γδ T-cells possess regulatory and cytotoxic capabilities, and could potentially influence the efficacy of immunotherapies. We analysed the frequencies of peripheral γδ T-cells, including their most prominent subsets (Vδ1+ and Vδ2+ cells) and differentiation states in 109 melanoma patients and 109 healthy controls. We additionally analysed the impact of γδ T-cells on overall survival (OS) calculated from the first dose of ipilimumab in melanoma patients. Higher median frequencies of Vδ1+ cells and lower median frequencies of Vδ2+ cells were identified in patients compared to healthy subjects (Vδ1+: 30% versus 15%, Vδ2+: 39% versus 64%, both p < 0.001). Patients with higher frequencies of Vδ1+ cells (≥30%) had poorer OS (p = 0.043) and a Vδ1+ differentiation signature dominated by late-differentiated phenotypes. In contrast, higher frequencies of Vδ2+ cells (≥39%) were associated with longer survival (p = 0.031) independent of the M category or lactate dehydrogenase level. Patients with decreasing frequencies of Vδ2+ cells under ipilimumab treatment had worse OS and a lower rate of clinical benefit than patients without such decreases. Therefore, we suggest frequencies of both Vδ1+ and Vδ2+ cells as candidate biomarkers for outcome in melanoma patients following ipilimumab. Further studies are needed to validate these results and to clarify whether they represent prognostic associations or whether γδ T-cells are specifically and/or functionally linked to the mode of action of ipilimumab.
Embargoed file
Embargoed file
Ne sera jamais visible
Loading...

Dates and versions

inserm-01408787 , version 1 (05-12-2016)

Identifiers

Cite

Kilian U Wistuba-Hamprecht, Alexander U Martens, Karin U Haehnel, Marnix A Geukes Foppen, Jianda U Yuan, et al.. Proportions of blood-borne Vd1þ and Vd2þ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. European Journal of Cancer, 2016, 64, pp.116-126. ⟨10.1016/j.ejca.2016.06.001⟩. ⟨inserm-01408787⟩
314 View
1 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More